I taught HS Biology for a few years so I’ll dig

I taught HS Biology for a few years so I’ll dig back into my teaching bag.

AAV allows the recipe to make LL to be taken to the nucleus of these muscle cells (myocytes). Then it undergoes the processes of transcription and translation where LL is manufactured. There are quality control mechanisms that make sure it is processed correctly and folded the right way, etc. Sometimes errors occur, actually many times errors occur, but those mistakes are usually discarded and not allowed to exit the cell. Later, LL is “packaged” in Another area of the cell called the Golgi apparatus. This packaging happens with all proteins that are made in the cell that are going to be secreted outside of the cell. These “packages” move to the cell membrane and fuse with it, and the formerly enveloped proteins are secreted into other tissues or the blood And out of the cell they were manufactured in.

I’m wondering if something happened with some of the LL in the quality control that allowed improper forms of LL to be released into the blood and antibodies are then made to meet this foreign substance? Normal LL is foreign as well But again, I don’t remember anti-LL Antibodies being an issue in the past? The big question I have, and more importantly, the guys at OHSU, is why are these antibodies forming and, temporarily at least, preventing the intended therapeutic effect?

I’m just trying to get my head wrapped around why these antibodies would be forming and interfering with the intention of a functional cure. It may have nothing to do with transcription, translation, or exocytosis.

I’m not trying to confuse anyone But I know there are people on this board who are scientifically trained and are wondering the same thing.